Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source
VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model.
Scientific reports · 2016
Study scale: CBA/J × DBA/2 pregnant mice were treated in vivo with VIP or PBS, as described, and at day 8.5 the implantation sites were obtained and Foxp3/RORγt expression ratio was evaluated by RT-PCR.
Abstract only: Open source record
Product or molecular entity relationships
- VIP: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Public plain-language summary
Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
In this sense, we investigated whether the in vivo treatment with VIP contributes to an immunosuppressant local microenvironment associated with an improved pregnancy outcome in the CBA/J × DBA/2 resorption prone model.
Study design
This local tolerogenic microenvironment is also accompanied by a decrease in T-bet (transcriptor factor associated with a Th1 profile) and RORγt expression (transcription factor associated with a Th17 profile) in several ex vivo and mice models1112131415.
Participants or experimental system
Moreover, VIP modulated the maternal peritoneal macrophages efferocytosis ability, tested using latex beads-FITC or apoptotic thymocytes, displaying an increased frequency of IL-10-producer F4/80 cells while did not modulate TNF-α and IL-12 secretion.
Study scale
CBA/J × DBA/2 pregnant mice were treated in vivo with VIP or PBS, as described, and at day 8.5 the implantation sites were obtained and Foxp3/RORγt expression ratio was evaluated by RT-PCR.
Intervention or exposure
VIP treatment (2 nmol/mouse i.p.) on day 6.5 significantly increased the number of viable implantation sites and improved the asymmetric distribution of implanted embryos.
Comparator
Since the control of the initial inflammatory response after embryo implantation is crucial for a successful pregnancy outcome12 and considering that VIP mediates anti-inflammatory and tolerogenic immune effects, we hypothesized that VIP participates in homeostasis maintenance at the early maternal-placental interface inducing an immunosuppresant microenvironment through maternal macrophage efferocytosis associated with an alternative activation profile.
Outcomes examined
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Key findings
Pregnancy induced the expression of VIP, VPAC1 and VPAC2 in the uterus from CBA/J × DBA/2 mating females on day 8.5 of gestation compared with non-pregnant mice.
Limitations and uncertainty
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.